EP4157326A1 - Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire - Google Patents

Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire

Info

Publication number
EP4157326A1
EP4157326A1 EP21730985.5A EP21730985A EP4157326A1 EP 4157326 A1 EP4157326 A1 EP 4157326A1 EP 21730985 A EP21730985 A EP 21730985A EP 4157326 A1 EP4157326 A1 EP 4157326A1
Authority
EP
European Patent Office
Prior art keywords
vitamin
zinc
combination
selenium
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21730985.5A
Other languages
German (de)
English (en)
Inventor
Carmelo SCARPIGNATO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofarma SRL
Original Assignee
Apharm SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT102020000012754A external-priority patent/IT202000012754A1/it
Application filed by Apharm SRL filed Critical Apharm SRL
Publication of EP4157326A1 publication Critical patent/EP4157326A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • Subject-matter of the present invention is a combination of active ingredients, nutraceutical and/or pharmaceutical compositions containing it and their use to support and enhance the functionality of the immune system and/or as adjuvants in counteracting the cold-related diseases.
  • the immune system is constituted by a complex integrated network of chemical and cellular mediators, biological structures and processes, which have been developed in the course of the evolution, to defend the organism from the external insults that may result, for example, from trauma or infectious agents.
  • the immune system must be able to detect a wide variety of external "dangers” and pathogens and distinguish them from the healthy tissue of the organism it must defend.
  • immunodeficiency When the immune system is less active than normal, we talk about immunodeficiency. This condition, which can be either genetic or due to diseases, caused by stress or the use of immunosuppressive drugs, can have more or less debilitating consequences depending on its severity, determining for example, in the most common cases, a greater tendency to get sick or recurrent infections.
  • Maintaining/enhancing a healthy immune system can be the basis of a prophylactic therapy against infections, in particular cold-related infections, which affect the entire population but, in particular and with more serious consequences, people who are less prepared to deal with them.
  • nutraceutical or phytopharmaceutical preparations are known and on the market.
  • a combination of nutraceutical/phytopharmaceutical active ingredients with immunomodulatory effect may act at different stages and levels of the pathogenesis of the cold-related infections.
  • it can be useful to counteract them both at a very early stage of the infection, at the level of the colonization and penetration of the anatomical barriers by the infectious agent, and at more advanced levels such as the spread of the pathogen in the body and especially during its response to the infection (e.g., oxidative stress, inflammation).
  • one of the best known and most pursued approaches to improve the health state of the immune system is the one related to the administration of probiotics, which are known to be able to modulate the mucosal immunity and interact with the cells of the immune system.
  • the products containing probiotics provide for a complicated development process that starts with the selection of the strains, which must be able to resist to the acids and bile, must remain viable and reproduce, adhere to the cells of the intestinal epithelium and colonize it by producing, with their metabolism, substances useful to the "host” organism and acting as antagonists for pathogenic bacteria.
  • the formulation must also be designed to protect them and get them active and in sufficiently large numbers to the site of action.
  • these products can be inconvenient to use, many for example need to be stored in the refrigerator at temperatures between 3 and 6°C.
  • a further approach involves the use of products known in the phytopharmaceutical field, such as for example Echinacea or Ginseng extracts, which are traditionally known for their immunostimulating/energizing activities.
  • Echinacea or Ginseng extracts which are traditionally known for their immunostimulating/energizing activities.
  • these compounds intrinsically have some disadvantages linked to their direct natural derivation which implies a variable concentration of active ingredients inside the extract, possible interactions and side effects not always documented, dosages not exactly tabulated. Therefore, there is a need to provide novel nutraceutical combinations useful to support and strengthen the immune system that are effective and safe to use and able to overcome the disadvantages in the prior art.
  • An object of the present invention is to provide a novel combination of active ingredients having immunostimulating action useful to support and enhance the function of the immune system.
  • Another object of the present invention is to provide a novel composition comprising said combination suitable in particular, but not only, for supporting and strengthening the immune system and/or counteracting and/or preventing the cold- related diseases.
  • a further object of the invention is the possibility of using the combination and composition subj ect of the invention, as an adjuvant in the prevention and/or treatment against the cold-related diseases.
  • subject-matter of the invention is a combination consisting of lactoferrin, N-acetylcysteine (NAC), resveratrol, vitamin D, vitamin C, Zinc, Selenium and optionally curcumin.
  • Lactoferrin is a natural iron-binding glycoprotein known for its ability to inhibit the bacterial growth and prevent viral infections by preventing their penetration into the host cells.
  • N-acetylcysteine is a molecule widely used as a mucolytic agent, it has a strong effect as an antioxidant and acts, at the intracellular level, as a precursor of glutathione.
  • Resveratrol chemically 5-[2E-(4-hydroxyphenyl)-ethenyl]benzen-l,3-diol, is a natural polyphenolic molecule present in the grapevine with antioxidant action.
  • vitamin D denotes a group of fat-soluble secosteroids that are particularly useful for the intestinal absorption of minerals and many other biological functions.
  • vitamin D means vitamin D3, also called cholecalciferol, which is also produced by the human body starting from 7-dehydrocholesterol by the action of the UVB rays, has receptors present in every part of the body and is linked to numerous processes not only at the level of the skeleton but also of an anti-inflammatory type by reducing, for example, the production of cytokines.
  • the indicated amounts of vitamin D3 refer to cholecalciferol, although in the combination and compositions of the invention said cholecalciferol may be introduced in the form of substances comprising it.
  • Vitamin C also called L-ascorbic acid
  • Vitamin C is an essential micronutrient with many different functions at the level of the cellular biochemical processes and has a strong antioxidant activity. Its deficiency leads, among other problems, to a reduced ability of the immune system to respond to the infections.
  • the indicated amounts of vitamin C refer to the L-ascorbic acid, although in the combination and compositions of the invention said L-ascorbic acid may be introduced in the form of substances comprising it.
  • Zinc and Selenium are essential minerals that become part of numerous biochemical chains within the human body.
  • these minerals may be present in the form of oxides, salts, esters, complexes and the like.
  • Zinc of the combination is present in the form of Zinc oxide.
  • Selenium is in the form of Sodium Selenite.
  • Zinc is in the form of Zinc oxide and Selenium is in the form of Sodium Selenite.
  • Curcumin is a molecule that is generally extracted from turmeric, preferably Curcuma longa.
  • curcumin may be used in pure form or in crude extract form or in any other form.
  • said curcumin preferably extracted from Curcuma longa, can be used in phytosomal form, i.e., conjugated with phospholipids, advantageously with soybean phospholipids.
  • said curcumin may be in the form of a hydroalcoholic extract of Turmeric, preferably of Curcuma longa.
  • the combination of the invention comprises curcumin.
  • the combination has been found to be particularly useful and effective in supporting and strengthening the immune system and/or as an adjuvant in the prevention and/or treatment of the cold-related diseases.
  • the combination has shown interesting immunostimulating activities thanks to the combined and synergistic action of its components, particularly when they are dosed according to the aforementioned weight ratios.
  • the terms “immunostimulation”, “immune system strengthening”, with all synonyms for the word “strengthening”, are meant be equivalent.
  • “immunostimulation” and derived terms it is meant here to denote the activity of stimulating the body's own immune defenses so that it can react more promptly and effectively against the external attacks such as the infections by pathogens of any kind, such as bacteria, viruses, fungi, protozoa, etc.
  • cold-related diseases it is meant here that class of diseases/infections determined by the presence of pathogens that affect the sense organs of the head (nose, eyes, ears), throat and lungs (at all levels) and that comprise, for example but not only, flu, cold, otitis, pharyngitis, bronchitis etc.
  • the components are present in the following weight ratios: lactoferrin/N- acetylcysteine/resveratrol/vitamin D/vitamin C/Zinc/Selenium, 1/1-3/0.1-0.5/0.0001- 0.0005/1-4/0.001-0.05/0.0001-0.0005, preferably 1/1-2/0.1-0.3/0.0001-0.0002/1.5- 3/0.02-0.04/0.00015-0.0004, more preferably about
  • the components are present in the following weight ratios: lactoferrin/N- acetylcysteine/resveratrol/vitamin D/vitamin C/Zinc/Selenium/curcumin, 1/1-3/0.1- 0.5/0.0001-0.0005/1-4/0.001-0.05/0.0001-0.0005/0.01-0.5, preferably 1/1-2/0.1- 0.3/0.0001-0.0002/1.5-3/0.02-0.04/0.00015-0.0004/0.03-0.3, more preferably about 1/1.5/0.25/0.000125/2.5/0.0375/0.00025/0.05-0.2.
  • Zinc and Selenium are counted as pure elements (i.e., based on their atomic weight). Therefore, even when in the combination of the invention such elements are used in different forms, such as oxides, salts or complexes, the quantities referred to in the aforementioned weight ratios are always referred to the two elements only.
  • the amounts of curcumin are always calculated on the basis of curcumin, even when used in phytosomal form or complexed in other forms.
  • the combination is preferably formulated in compositions suitable for the administration by oral route, with immediate or controlled release, for example in suitable oral dosage forms, as solid dosage units, such as capsules, tablets, effervescent tablets, powders or granules, or in liquid dosage forms such as mono- or multi-dose oral solutions or suspensions.
  • suitable oral dosage forms as solid dosage units, such as capsules, tablets, effervescent tablets, powders or granules, or in liquid dosage forms such as mono- or multi-dose oral solutions or suspensions.
  • Said composition preferably an oral composition, more preferably an oral solid composition, advantageously with immediate release, comprising the combination of the invention together with pharmaceutically acceptable excipients and carriers, is a further subject- matter of the invention.
  • the composition of the invention comprises curcumin.
  • compositions of the invention may contain conventionally used excipients, for example, diluting agents, adsorbents, lubricants, glidants, sweeteners, colorants, effervescents, etc.
  • the combination of the invention may be administered in compositions comprising one or more pharmaceutically acceptable excipients, in daily dosages of: 100 to 300 mg lactoferrin, preferably 150 to 250, even more preferably about 200 mg;
  • resveratrol 20 to 100 mg resveratrol, preferably 35 to 75 mg, even more preferably about 50 mg;
  • Zinc preferably 6 to 8 mg, even more preferably about 7.5 mg;
  • the combination of the invention may be administered in compositions comprising one or more pharmaceutically acceptable excipients, in daily dosages of:
  • lactoferrin 100 to 300 mg lactoferrin, preferably 150 to 250, even more preferably about 200 mg;
  • resveratrol 20 to 100 mg resveratrol, preferably 35 to 75 mg, even more preferably about 50 mg;
  • Zinc preferably 6 to 8 mg, even more preferably about 7.5 mg;
  • such daily dosages may be increased or reduced, for example also doubled.
  • the afore stated daily dosages are taken in a single daily administration.
  • said dosages can be administered in a single dose or divided in two or more administrations, for example one, two or three daily administrations, to be taken simultaneously or at different times.
  • the combination is in the form of oral solid compositions and packaged in capsules, sachets or tablets, if desired also effervescent tablets.
  • the combination is in the form of oral solid compositions such as powder or granules and packaged in stick packs or sachets.
  • compositions of the invention can be defined as pharmaceutical or nutraceutical compositions.
  • said daily dosages or the compositions of the invention are administered on a full stomach, for example after breakfast or after lunch.
  • the preferred solid oral composition according to the invention for example a capsule, a tablet or a granule to be packaged in sachets, it is possible to use the methods known in the art.
  • the tablets may also be prepared by the addition of excipients which allow them to be administered after being dissolved in an aqueous vehicle, such as for example by the addition of effervescent excipients or by technologies to make them orosoluble.
  • Capsules and tablets may also be coated with a film, which may be of cosmetic or functional type, for example to achieve a gastro- resistant form or a controlled/ sustained release.
  • the techniques for preparing effervescent, orosoluble dosage forms and those for applying a coating film are those known in the field of pharmaceutical technology and known to the expert in the art.
  • compositions of the invention are administered orally.
  • compositions of the invention are administered in oral dosage forms, each comprising:
  • lactoferrin preferably 150 to 250, even more preferably about 200 mg;
  • resveratrol preferably 35 to 75 mg, even more preferably about 50 mg;
  • Zinc preferably 6 to 8 mg, even more preferably about 7.5 mg;
  • compositions of the invention are administered in oral dosage forms, each comprising:
  • lactoferrin preferably 150 to 250, even more preferably about 200 mg;
  • resveratrol preferably 35 to 75 mg, even more preferably about 50 mg;
  • curcumin preferably 10 to 40 mg, even more preferably about 20 mg; optionally together with pharmaceutically acceptable excipients and carriers.
  • compositions according to the invention are provided in the Experimental section, by way of illustration.
  • the combination of the invention is particularly recommended in clinical conditions in which a functional deficiency of the immune system is present.
  • compositions as described above to support and strengthen the immune system and/or as an adjuvant in the prevention and/or treatment of cold- related diseases constitutes a further subject-matter of the invention.
  • a subject-matter of the invention is a method for obtaining an immunostimulant effect and/or as an adjuvant for treating and/or preventing the disorders of the cold-related diseases, comprising administering an effective dose of the combination or composition of the invention to a subject in the need thereof.
  • subject is meant herein to denote a mammal, preferably a human.
  • composition of the invention itself provides the solution to the problem, if desired or needed, other substances however beneficial for the body can be added to the compositions of the present invention, provided they do not counteract the effects of the combination and composition of the invention.
  • the invention will now be described for illustrative purpose only and in no way limiting in the Experimental Section below.
  • Sachet of granules comprising:
  • Zinc oxide 9.4 mg (corresponding to 7.5 mg Zinc);
  • Sachet of granules comprising:
  • Vitamin D 40 pg Vitamin D 40 pg
  • Zinc oxide 12.4 mg (corresponding to 10 mg Zinc);
  • Curcumin 20 mg together with conventional vehicles and excipients.
  • Hard gelatin capsule comprising:
  • Vitamin D 12.5 pg; Vitamin C 250 mg;
  • Zinc oxide 12.4 mg (corresponding to 10 mg Zinc);
  • Sachet of granules comprising:
  • Zinc oxide 18.8 mg (corresponding to 15 mg Zinc);
  • Sachet of granules comprising:
  • Zinc oxide 18.8 mg (corresponding to 15 mg Zinc);
  • Sachet of granules comprising:
  • Zinc oxide 12.4 mg (corresponding to 10 mg Zinc);
  • Hard gelatin capsule comprising:
  • Zinc oxide 12.4 mg (corresponding to 10 mg Zinc);

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une combinaison de principes actifs, les compositions nutraceutiques et/ou pharmaceutiques les contenant et leur utilisation pour soutenir et améliorer la fonctionnalité du système immunitaire et/ou en tant qu'adjuvants pour lutter contre les maladies liées au froid.
EP21730985.5A 2020-05-28 2021-05-17 Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire Pending EP4157326A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102020000012754A IT202000012754A1 (it) 2020-05-28 2020-05-28 Associazione di principi attivi, composizioni che la contengono e loro uso per sostenere e rafforzare il sistema immunitario.
IT202100003101 2021-02-11
PCT/IB2021/054197 WO2021240293A1 (fr) 2020-05-28 2021-05-17 Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire

Publications (1)

Publication Number Publication Date
EP4157326A1 true EP4157326A1 (fr) 2023-04-05

Family

ID=76325578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21730985.5A Pending EP4157326A1 (fr) 2020-05-28 2021-05-17 Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire

Country Status (2)

Country Link
EP (1) EP4157326A1 (fr)
WO (1) WO2021240293A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024018374A1 (fr) 2022-07-20 2024-01-25 Frimline Private Limited Composition pharmaceutique assurant un effet mucolytique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation
US20080317725A1 (en) * 2007-06-20 2008-12-25 Baum Seth J Compositions and methods of treating chronic kidney disease
US20130064804A1 (en) * 2011-09-14 2013-03-14 Naidu Lp BIO-REPLENISHMENT (BioRep) FOR IMPROVING SLEEP ARCHITECTURE
US20140127179A1 (en) * 2012-11-02 2014-05-08 Scientific Formulations, Llc Natural Killer Cell Formulations

Also Published As

Publication number Publication date
WO2021240293A1 (fr) 2021-12-02

Similar Documents

Publication Publication Date Title
US5932624A (en) Vitamin supplement composition
Islam et al. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19
EP2288364B1 (fr) Procédés de traitement ou de prévention du diabète mellitus et autres déséquilibres métaboliques
JP2008542300A (ja) 炎症と関連した状態を予防及び治療するための組成物及び方法
AU2011282200B2 (en) Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment
WO2001003696A1 (fr) Compositions pharmaceutiques et nutritionnelles renfermant des acides gras essentiels et des agents de reduction de l'homocysteine
EP3027056B1 (fr) Composition pour ameliorer l'immunite
JP6660289B2 (ja) ニワトコ抽出物とラクトバチルス・ラムノーサスの菌株との組合せを含んでなる組成物
AU2017253087A1 (en) Compositions and methods for improved restoration and preservation of the integrity of tissue barriers
GB2368012A (en) Preparation for the relief of inflammatory disease
EP2364139A2 (fr) Compositions à base de ngna et procédés d'utilisation
WO2018039755A1 (fr) Formulation pharmaceutique à base de zinc et de quercétine pour la production d'un médicament antiviral efficace contre la dengue et zika
WO2021240293A1 (fr) Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire
US10149831B1 (en) Pharmaceutical composition for treating bacterial and viral infections
WO2005051370A1 (fr) Composition a effet protecteur des fonctions hepatiques
WO2019155360A2 (fr) Composition pharmaceutique permettant de traiter des infections bactériennes et virales
CA2346647C (fr) Traitement de la dyspepsie
CN106349318B (zh) 一种五环三萜化合物在制备治疗肥胖症药物中的应用
WO2022091023A1 (fr) Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire
Karki et al. Potential role of nutrients in immune boosting and aiding against COVID19 pathogenesis
WO2021092120A1 (fr) Procédés et compositions pour améliorer l'état de santé général et la longévité chez les mammifères
IT202000012754A1 (it) Associazione di principi attivi, composizioni che la contengono e loro uso per sostenere e rafforzare il sistema immunitario.
Upadhyay et al. Inflammatory bowel diseases (IBDs)
WO2022024147A1 (fr) Compositions de protéine de lactosérum lactoferrine et de poudre de graines de fruits du jacquier
JP2006104080A (ja) 痛風と尿酸による血流障害の予防又は治療効果のある組成物及び健康食品。

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230520

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOFARMA S.R.L.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240523